肺癌切除术后并发症与淋巴结采样标准的相关性
该回顾性队列研究纳入2018—2023年单医疗系统964例择期肺癌切除患者,比较ACS CoC与ESTS淋巴结采样标准与术后并发症的关系。结果显示不同标准间30天总体并发症风险调整后无显著差异,但符合ESTS标准者主要并发症较低(aRR 0.76,95%CI 0.68-0.86)。
要点
- 符合ACS CoC、ESTS及均不符合标准的患者分别占54.4%、12.6%和44.4%。
- 三种采样标准间30天总体并发症风险调整后无显著差异。
- 符合ESTS标准者主要30天并发症风险调整后较低(aRR 0.76,95%CI 0.68-0.86)。
核心结论
- 不同淋巴结采样标准间30天总体并发症风险调整后无显著差异。
- 符合ESTS标准者主要30天并发症风险调整后低于ACS CoC标准及均不符合标准者。
- 优化淋巴结评估质量时,采样相关术后并发症可能不如肿瘤学结局重要。
研究设计与样本
- 回顾性队列分析,纳入2018—2023年单医疗系统择期肺癌切除患者共964例。
- 采用多变量Poisson回归伴稳健方差评估30天总体及主要术后并发症与采样标准的关系。
主要发现
- 524例(54.4%)符合ACS CoC标准,121例(12.6%)符合ESTS标准,428例(44.4%)均不符合。
- 30天总体并发症风险调整后发生率:ACS CoC组29.8%,ESTS组27.8%,均不符合组34.4%,组间无显著差异。
- 主要30天并发症风险调整后发生率:ACS CoC组17.7%,均不符合组13.6%,ESTS组13.6%(aRR 0.76,95%CI 0.68-0.86)。
关键数值与推荐
- ACS CoC推荐从3个纵隔站和1个肺门站采样淋巴结。
- ESTS推荐肺叶特异性淋巴结站采样策略。
临床怎么用
- 选择淋巴结采样标准时可更多考虑肿瘤学获益而非术后并发症差异。
- ESTS标准与较低的主要30天并发症风险调整后发生率相关,可作为参考。
局限性
- 单医疗系统回顾性队列设计,可能存在选择偏倚和混杂。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American College of Surgeons Commission on Cancer (ACS CoC) has recommended lymph node sampling from 3 mediastinal stations and 1 hilar station, while the European Society of Thoracic Surgeons (ESTS) has recommended a lobe-specific lymph node station sampling strategy for lung cancer resection. Comparative postoperative complications associated with these strategies are unknown. The objective of this study is to evaluate the association of lymph node sampling strategy on postoperative outcomes for lung cancer patients. METHODS: We conducted a retrospective cohort analysis of elective lung cancer resections from 2018-2023 in a single health system. We performed multivariable Poisson regression with robust variance to evaluate the association of any 30-day postoperative complications and major 30-day postoperative complications across lymph node sampling criteria. RESULTS: Of 964 total patients, 524 (54.4%) met ACS CoC, 121 (12.6%) met ESTS, and 428 (44.4%) met neither criteria. Risk-adjusted rates of 30-day postoperative complications were not significantly different between ACS CoC (29.8%), ESTS (27.8%), and neither criteria (34.4%). Risk-adjusted rates of major 30-day postoperative complications were similar between ACS CoC (17.7%) and neither criteria (13.6%) but lower for those meeting ESTS criteria (13.6%, aRR 0.76 95% CI 0.68-0.86). CONCLUSIONS: There were no risk-adjusted differences in any 30-day postoperative complications between lymph node sampling criteria. These findings suggest that postoperative morbidity associated with lymph node sampling criteria may be less important than considering oncologic outcomes for optimizing quality of lymph node evaluation.
引用
- Jacobs RC, Visa MA, Chang AB, et al. Association of Postoperative Complication and Lymph Node Sampling Criteria in Lung Cancer Resection. J Am Coll Surg. 2025. PMID: 40932125. doi:10.1097/XCS.0000000000001625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。